US FDA warns of meningitis risk with GSK's Lamictal
This article was originally published in Scrip
Executive Summary
The US FDA has issued a safety warning for GlaxoSmithKline's Lamictal (lamotrigine) over an increased risk of aseptic meningitis associated with its use. The agency is revising the warnings and precautions section of the drug's label and patient medication guide to include information about the risk following reports of 40 cases of the disease in patients taking the drug.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.